Panacea Life Sciences Holdings, Inc.
Income Statement
| Line Item | FY2016 | FY2015 | FY2014 |
|---|---|---|---|
| Revenue | $0 | $213 | $852 |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $369.3K | $77.3K | $58.3K |
| SG&A Expense | $759.1K | $108.4K | $167.5K |
| Operating Income | $-1.6M | $-389.3K | $-420.3K |
| Operating Margin | — | -182,761.5% | -49,326.1% |
| Interest Expense | $0 | — | — |
| Pretax Income | $-1.6M | $-358.2K | $-296.6K |
| Income Tax Expense | $0 | $0 | — |
| Net Income | $-1.6M | $-358.0K | $-296.6K |
| Net Margin | — | -168,064.3% | -34,808.8% |
| EPS (Basic) | $-0.08 | $-0.70 | $-0.02 |
| EPS (Diluted) | $-0.08 | $-0.70 | $-0.02 |
| Shares Outstanding (Basic) | 34.1M | 515.3K | 15.1M |
| Shares Outstanding (Diluted) | 34.1M | 515.3K | 15.1M |
| Dividends Per Share | — | — | — |